RE: Board changes5 Sep 2024 13:33
Readig today's RNS again, hand in hand with news that PM is leaving the company at end year, is the statement, not to be overlooked: "With Synairgen's resources dedicated to the clinical development of SNG001, Dr. Marcin Mankowski became the Company's Chief Medical Officer in 2023 and will continue to lead the clinical development strategy for SNG001." Then they thank "Phill for his significant contribution over many years, particularly for progressing the early-stage clinical development of SNG001". The key takeaway for me is that development is entering a new phase where early science is all but complete and this now necessitates a transition from the lab to commercialisation. It wil be interesting to see the nature of the further BOD changes they mention.